tiprankstipranks
MEDIROM Healthcare Technologies (MRM)
NASDAQ:MRM
US Market
Want to see MRM full AI Analyst Report?

MEDIROM Healthcare Technologies (MRM) AI Stock Analysis

128 Followers

Top Page

MRM

MEDIROM Healthcare Technologies

(NASDAQ:MRM)

Select Model
Select Model
Select Model
Neutral 58 (OpenAI - 5.2)
Rating:58Neutral
Price Target:
$1.50
▲(51.52% Upside)
Action:Reiterated
Date:11/04/25
The overall stock score is primarily influenced by financial performance and technical analysis. While the company shows strong revenue growth, profitability and liquidity challenges are significant concerns. The technical indicators suggest a bearish trend, but the stock appears undervalued based on its P/E ratio.
Positive Factors
Recurring & Diversified Revenue Model
MEDIROM’s mix of tiered telemedicine subscriptions, product sales and service agreements builds recurring and diversified revenues. That business model provides predictable cash inflows, cross-sell opportunities and resilience versus single-product firms, supporting steadier medium-term growth.
Negative Factors
High Leverage / Low Equity Ratio
A low equity ratio and material debt-to-equity indicate heavy reliance on debt financing. Elevated leverage raises interest expense and refinancing sensitivity, limiting strategic flexibility and increasing solvency risk if operational performance weakens over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring & Diversified Revenue Model
MEDIROM’s mix of tiered telemedicine subscriptions, product sales and service agreements builds recurring and diversified revenues. That business model provides predictable cash inflows, cross-sell opportunities and resilience versus single-product firms, supporting steadier medium-term growth.
Read all positive factors

MEDIROM Healthcare Technologies (MRM) vs. SPDR S&P 500 ETF (SPY)

MEDIROM Healthcare Technologies Business Overview & Revenue Model

Company Description
MEDIROM Healthcare Technologies Inc. (MRM) is a Japanese company that offers comprehensive healthcare solutions, operating through two primary divisions: Relaxation Salon and Digital Preventative Healthcare. The Relaxation Salon segment oversees a...
How the Company Makes Money
MEDIROM Healthcare Technologies generates revenue through multiple channels, including subscription fees for its telemedicine services, sales of wellness and diagnostic products, and partnerships with healthcare providers and institutions. The com...

MEDIROM Healthcare Technologies Financial Statement Overview

Summary
MEDIROM Healthcare Technologies shows strong revenue growth but faces profitability challenges and high leverage. The balance sheet has improved equity, yet high debt levels pose risks. Cash flow issues, particularly negative free cash flow, highlight liquidity concerns.
Income Statement
65
Positive
Balance Sheet
50
Neutral
Cash Flow
40
Negative
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue7.98B8.30B6.83B6.95B5.41B3.34B
Gross Profit2.01B2.25B1.57B1.90B1.42B428.95M
EBITDA258.25M387.50M310.08M373.63M-276.29M-551.16M
Net Income59.89M148.76M115.05M148.97M-990.73M-539.17M
Balance Sheet
Total Assets7.98B8.09B6.85B6.75B5.75B5.71B
Cash, Cash Equivalents and Short-Term Investments38.76M335.56M132.85M605.95M377.12M1.47B
Total Debt3.91B3.96B3.65B3.23B2.79B2.56B
Total Liabilities7.49B6.90B6.63B6.81B5.96B5.22B
Stockholders Equity442.34M933.27M210.88M-59.38M-208.34M491.26M
Cash Flow
Free Cash Flow-1.45B-1.90B-767.58M-806.44M-652.88M-439.98M
Operating Cash Flow-887.98M-1.33B-631.74M-685.70M-557.23M-366.42M
Investing Cash Flow-438.95M361.39M-328.58M580.44M-83.94M-139.60M
Financing Cash Flow1.22B1.19B461.21M340.10M-427.95M1.43B

MEDIROM Healthcare Technologies Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.99
Price Trends
50DMA
1.06
Negative
100DMA
1.11
Negative
200DMA
1.49
Negative
Market Momentum
MACD
-0.03
Negative
RSI
45.49
Neutral
STOCH
78.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRM, the sentiment is Negative. The current price of 0.99 is above the 20-day moving average (MA) of 0.98, below the 50-day MA of 1.06, and below the 200-day MA of 1.49, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 45.49 is Neutral, neither overbought nor oversold. The STOCH value of 78.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRM.

MEDIROM Healthcare Technologies Risk Analysis

MEDIROM Healthcare Technologies disclosed 60 risk factors in its most recent earnings report. MEDIROM Healthcare Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

MEDIROM Healthcare Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
$68.42M0.5859.91%14.95%29.24%
61
Neutral
$18.38B12.79-2.54%3.03%1.52%-15.83%
58
Neutral
$7.51M-1.94-68.38%
40
Neutral
$3.68M-0.501.38%-1.57%
38
Underperform
$9.84M-135.73%39.27%-230.99%
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MRM
MEDIROM Healthcare Technologies
0.95
-0.38
-28.57%
RGS
Regis
27.38
8.06
41.72%
EJH
E-Home Household Service Holdings
1.15
-35.60
-96.87%
YYGH
YY Group Holding Limited Class A
1.20
-3,688.80
-99.97%

MEDIROM Healthcare Technologies Corporate Events

MEDIROM MOTHER Labs Triples REMONY Deployment with New JGSDF 8th Division Order
Jun 25, 2026
On June 25, 2026, MEDIROM MOTHER Labs, a subsidiary of MEDIROM Healthcare Technologies, announced that it received an additional order from the Japan Ground Self-Defense Force’s 8th Division for its REMONY remote health monitoring system, wh...
MEDIROM Faces Nasdaq Non-Compliance Notice Over Delayed 20-F Filing
May 29, 2026
MEDIROM Healthcare Technologies Inc., a Japan-based operator of roughly 300 Re.Ra.Ku wellness salons and a developer of HealthTech solutions such as the Lav training app and MOTHER Bracelet smart tracker, straddles the consumer wellness and remote...
MEDIROM Posts Q1 2026 KPIs as Hybrid Staffing and World ID Partnership Gain Traction
May 28, 2026
MEDIROM Healthcare Technologies reported first-quarter 2026 performance on May 28, 2026, highlighting a salon business that continues to command premium pricing, with average revenue per customer rising 7.7% year on year to 7,822 yen, well above t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 04, 2025